Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicals[1]
- Market Cap ₹ 17.2 Cr.
- Current Price ₹ 46.0
- High / Low ₹ 54.0 / 24.2
- Stock P/E
- Book Value ₹ -0.27
- Dividend Yield 0.00 %
- ROCE -58.5 %
- ROE -195 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.67% over past five years.
- Promoter holding is low: 30.8%
- Company has a low return on equity of -38.9% over last 3 years.
- Debtor days have increased from 29.5 to 60.3 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 22.69 | |
0.03 | 0.02 | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 23.93 | |
Operating Profit | -0.03 | -0.02 | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | -1.24 |
OPM % | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.62% | -30.58% | -5.46% | |||||
0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.10 | 0.09 | 0.06 | 0.04 | 0.05 | 0.15 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.56 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.66 |
Profit before tax | -0.03 | 0.04 | 0.04 | 0.01 | 0.01 | 0.00 | 0.10 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -3.31 |
Tax % | 0.00% | 0.00% | 25.00% | 200.00% | 100.00% | 20.00% | 41.10% | 38.02% | 54.84% | 375.00% | 2.12% | ||
-0.03 | 0.04 | 0.02 | 0.00 | -0.01 | 0.00 | 0.08 | 0.43 | 0.75 | 0.14 | -0.10 | -5.78 | -3.41 | |
EPS in Rs | -0.08 | 0.10 | 0.05 | 0.00 | -0.03 | 0.00 | 0.21 | 1.15 | 2.00 | 0.37 | -0.27 | -15.45 | -9.12 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -25% |
TTM: | 32% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -433% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 4% |
1 Year: | 46% |
Return on Equity | |
---|---|
10 Years: | -9% |
5 Years: | -18% |
3 Years: | -39% |
Last Year: | -195% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.90 | 3.90 | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
Reserves | 0.06 | 0.09 | 0.12 | 0.11 | 0.10 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.40 | -4.38 | -4.55 |
0.90 | 0.92 | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 5.75 | |
0.08 | 0.09 | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.35 | 9.51 | |
Total Liabilities | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 15.16 |
2.53 | 2.53 | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.50 | 9.27 | 8.76 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 1.25 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 |
2.41 | 2.47 | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 5.15 | |
Total Assets | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 15.16 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -0.01 | -0.06 | 0.00 | -0.50 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.19 | |
0.00 | 0.00 | 0.00 | 0.00 | -0.19 | -4.23 | -3.41 | -2.40 | -3.15 | -1.53 | -0.94 | -1.59 | |
0.03 | 0.01 | 0.00 | 0.10 | 0.56 | 1.14 | 3.10 | -0.23 | 0.40 | -0.91 | -0.04 | 1.43 | |
Net Cash Flow | 0.00 | 0.00 | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.20 | 0.78 | -1.69 | -0.65 | -0.35 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.70 | 60.28 | |||||
Inventory Days | 203.34 | 278.66 | 88.17 | 107.27 | 154.80 | 286.55 | 123.74 | |||||
Days Payable | 609.39 | 645.07 | 311.84 | 269.40 | 299.82 | 309.82 | 382.60 | |||||
Cash Conversion Cycle | -345.57 | -331.40 | -166.09 | -139.12 | -131.41 | -8.57 | -198.58 | |||||
Working Capital Days | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -115.59 | |||||
ROCE % | -0.62% | 0.82% | 0.81% | 0.20% | 0.19% | 0.66% | 1.56% | 8.40% | 14.34% | 6.13% | 3.67% | -58.49% |
Documents
Announcements
- Financial Results For The Quarter And Half Year Ended On 30Th September, 2024 15 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Of PARMAX PHARMA LIMITED Held O 14Th November, 2024
15 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 SEBI (LODR) Regulations, 2015 To Consider, Approve The Un-Audited Financial Results For The Quarter Ended 30Th September, 2024
6 Nov - Board meeting to approve Q2 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - Compliance certificate dated 1st October, 2024 under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended 30th September, 2024 received from M/S Purva Sharegistry …
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
2 Oct - Voting results and scrutinizer's report for AGM.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Business Overview:[1]
Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the formulation of Tablets, Ointments,
Capsules, and Injectables.